CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Submission of Matters to a Vote of Security Holders

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

We held our 2019 Annual Meeting of Stockholders on June 18, 2019. The board of directors solicited proxies to a proxy statement that we filed on April 30, 2019 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended on May 1, 2019 and May 8, 2019. There was no solicitation in opposition to the board’s solicitation.
At the meeting, holders of common stock were asked to consider and vote upon the five proposals set forth below. Each share of common stock was entitled to one vote with respect to each matter submitted to a vote at the meeting. Shares of common stock representing 15,888,537 votes, or 92.56% of the total votes attributable to all outstanding shares of common stock, were present in person or by proxy at the meeting.
The voting results reported below are final.
The matters considered and voted on by the stockholders at the meeting and the votes of the stockholders were as follows:

As a result of this vote, each of the five nominees was elected as a director to serve until the 2020 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Story continues below

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

An ad to help with our costs